Rx0000106 |
Neos Therapeutics, Inc. |
09/30/2020 |
70165002030 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 12.5 MG |
07/06/2020 |
36.00 |
396.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved.
All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
Rx0000106 |
Neos Therapeutics, Inc. |
09/30/2020 |
70165002530 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 15.7 MG |
07/06/2020 |
36.00 |
396.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved.
All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
Rx0000106 |
Neos Therapeutics, Inc. |
09/30/2020 |
70165003030 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 18.8 MG |
07/06/2020 |
36.00 |
396.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved.
All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
Rx0000106 |
Neos Therapeutics, Inc. |
09/30/2020 |
70165000530 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 3.1 MG |
07/06/2020 |
36.00 |
396.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved.
All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
Rx0000106 |
Neos Therapeutics, Inc. |
09/30/2020 |
70165001030 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 6.3 MG |
07/06/2020 |
36.00 |
396.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved.
All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
Rx0000106 |
Neos Therapeutics, Inc. |
09/30/2020 |
70165001530 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 9.4 MG |
07/06/2020 |
36.00 |
396.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved.
All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
Rx0000106 |
Neos Therapeutics, Inc. |
03/31/2020 |
70165020030 |
COTEMPLA XR-ODT 17.3MG 30 Tabs/Bottle |
01/01/2020 |
49.11 |
420.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
The price increase on Cotempla XR was taken to support factors impacting the business including increased manufacturing costs, increased cost from operations and increased distribution costs. |
None |
No Significant Change/Improvement to Drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug has not been acquired. |
Rx0000106 |
Neos Therapeutics, Inc. |
03/31/2020 |
70165030030 |
COTEMPLA XR-ODT 25.9MG 30 Tabs/Bottle |
01/01/2020 |
49.11 |
420.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
The price increase on Cotempla XR was taken to support factors impacting the business including increased manufacturing costs, increased cost from operations and increased distribution costs. |
None |
No Significant Change/Improvement to Drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug has not been acquired. |
Rx0000106 |
Neos Therapeutics, Inc. |
03/31/2020 |
70165010030 |
COTEMPLA XR-ODT 8.6MG, 30 Tabs/Bottle |
01/01/2020 |
49.11 |
420.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
The price increase on Cotempla XR was taken to support factors impacting the business including increased manufacturing costs, increased cost from operations and increased distribution costs. |
None |
No Significant Change/Improvement to Drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug has not been acquired. |
Rx0000204 |
Noden Pharma USA, Inc. |
06/30/2020 |
70839015030 |
Tekturna 150mg aliskirin tablets 30 tablet bottle |
04/20/2020 |
16.62 |
224.42 |
02/19/2026 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis AG |
199000000 |
None |
includes milestones, other non-included milestone payments. Acquired the worldwide rights to tekturna/rasilez. |
150.19 |
133.66 |
2007 |
58.50 |
None |
None |
Rx0000204 |
Noden Pharma USA, Inc. |
06/30/2020 |
70839030030 |
Tekturna 300mg aliskirin tablets 30 tablet bottle |
04/20/2020 |
20.97 |
283.13 |
02/19/2026 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis AG |
199000000 |
None |
includes milestones, other milestones not included. Acquired the worldwide rights to tekturna/rasilez. |
189.48 |
172.41 |
2007 |
73.80 |
None |
None |
Rx0000204 |
Noden Pharma USA, Inc. |
06/30/2020 |
70839011230 |
Tekturna HCT oral tablet 150mg aliskirin/12.5mg hydrochlorthiazide 30 tablet bottle |
04/20/2020 |
16.62 |
224.42 |
07/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis AG |
199000000 |
None |
includes milestones, other milestones not included. Acquisition of worldwide rights to tekturna/rasilez. |
150.19 |
136.66 |
2008 |
62.01 |
None |
None |
Rx0000204 |
Noden Pharma USA, Inc. |
06/30/2020 |
70839012530 |
Tekturna HCT oral tablet 150mg aliskirin/25mg hydrochlorothiazide 30 tablet bottle |
04/20/2020 |
16.62 |
224.42 |
07/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis AG |
199000000 |
None |
includes milestones, other milestones not included. Acquisition of entire worldwide rights to tekturna/rasilez. |
150.19 |
136.66 |
2008 |
62.01 |
None |
None |
Rx0000204 |
Noden Pharma USA, Inc. |
06/30/2020 |
70839031230 |
Tekturna HCT oral tablet 300mg aliskirin/12.5mg hydrochlorothiazide 30 tablet bottle |
04/20/2020 |
20.97 |
283.13 |
07/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis AG |
199000000 |
None |
includes milestones, other milestones not included. acquisition of entire worldwide rights to tekturna/rasilez |
189.48 |
172.41 |
2008 |
78.23 |
None |
None |
Rx0000204 |
Noden Pharma USA, Inc. |
06/30/2020 |
70839032530 |
Tekturna HCT oral tablet 300mg aliskirin/25mg hydrochlorothiazide 30 tablet bottle |
04/20/2020 |
20.97 |
283.13 |
07/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis AG |
199000000 |
None |
includes milestones, other milestones not included. Acquisition of entire worldwide rights to tekturna/rasilez |
189.48 |
172.41 |
2008 |
78.23 |
None |
None |
Rx0000226 |
Nostrum Laboratories, Inc. |
06/30/2020 |
29033002602 |
Calcium Acetate Oral Capsule 667mg 200count |
06/25/2020 |
90.36 |
140.36 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The Product was not acquired. |
Rx0000226 |
Nostrum Laboratories, Inc. |
03/31/2020 |
29033002901 |
Pindolol Oral Tablets, 10mg - 100ct |
01/06/2020 |
287.95 |
431.81 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
We did not acquire this item. We developed it at Nostrum |
Rx0000226 |
Nostrum Laboratories, Inc. |
03/31/2020 |
29033002801 |
Pindolol Oral Tablets, 5mg - 100ct |
01/06/2020 |
263.48 |
369.06 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
We did not acquire this item. We developed it at Nostrum. |
Rx0000226 |
Nostrum Laboratories, Inc. |
03/31/2020 |
70408014634 |
Promethazine HCL Oral Solution, 6.25mg/5mL - 473mL |
01/13/2020 |
159.56 |
170.55 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
12/11/2015 |
Sun Pharmaceuticals |
None |
1 |
None |
10.99 |
10.99 |
2009 |
10.99 |
None |
None |
Rx0000073 |
Novartis |
03/31/2020 |
00065027510 |
Azopt 1% Drops 10mL, 10pk |
01/03/2020 |
16.96 |
325.34 |
None |
Single Source Drug |
95822 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00065027515 |
Azopt 1% Drops 15mL, 15pk |
01/03/2020 |
25.44 |
487.96 |
None |
Single Source Drug |
95822 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00065853302 |
CIPRODEX 0.3% / 0.1%, Drops, 7.5pk |
01/03/2020 |
12.99 |
249.09 |
06/04/2025 |
Single Source Drug |
2459065 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078063968 |
Cosentyx 150mg/ml (Sensoready Pen x1) |
01/03/2020 |
362.52 |
5541.43 |
05/05/2033 |
Single Source Drug |
123823 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078063941 |
Cosentyx 150mg/ml (Sensoready Pen x2) |
01/03/2020 |
362.52 |
5541.43 |
05/05/2033 |
Single Source Drug |
615929 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078063997 |
Cosentyx 150mg/ml (Syringe x1) |
01/03/2020 |
362.52 |
5541.43 |
05/05/2033 |
Single Source Drug |
25407 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078063998 |
Cosentyx 150mg/ml (Syringe x2) |
01/03/2020 |
362.52 |
5541.43 |
05/05/2033 |
Single Source Drug |
74145 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00065924007 |
DUREZOL 0.05% 5mL, Drops, 5pk |
01/03/2020 |
10.26 |
196.80 |
None |
Single Source Drug |
1019407 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078065967 |
Entresto 24/26mg - Tabs, 180 Each Bottle |
01/03/2020 |
106.92 |
1634.28 |
11/27/2027 |
Single Source Drug |
35604 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078065920 |
Entresto 24/26mg - Tabs, 60 Each Bottle |
01/03/2020 |
35.64 |
544.76 |
11/27/2027 |
Single Source Drug |
1360497 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078077767 |
Entresto 49/51mg - Tabs, 180 Each Bottle |
01/03/2020 |
106.92 |
1634.28 |
11/27/2027 |
Single Source Drug |
33446 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078077720 |
Entresto 49/51mg - Tabs, 60 Each Bottle |
01/03/2020 |
35.64 |
544.76 |
11/27/2027 |
Single Source Drug |
886774 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078069667 |
Entresto 97/103mg - Tabs, 180 Each Bottle |
01/03/2020 |
106.92 |
1634.28 |
11/27/2027 |
Single Source Drug |
30547 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078069620 |
Entresto 97/103mg - Tabs, 60 Each Bottle |
01/03/2020 |
35.64 |
544.76 |
11/27/2027 |
Single Source Drug |
627167 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078060715 |
Gilenya, Capsule 0.5mg - 30 each bottle |
01/03/2020 |
451.59 |
8662.23 |
09/30/2032 |
Single Source Drug |
318725 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00065175007 |
Ilevro 0.3%, Drops, 1.7ml per bottle |
01/03/2020 |
15.13 |
290.21 |
03/31/2032 |
Single Source Drug |
245494 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00065175014 |
Ilevro 0.3%, Drops, 3mL per bottle |
01/03/2020 |
15.13 |
290.21 |
03/31/2032 |
Single Source Drug |
169319 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078090961 |
Kisqali + Femara Co-Pack 200 mg, 49 tabs per bottle |
01/03/2020 |
276.16 |
5297.34 |
11/09/2031 |
Single Source Drug |
300 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078091661 |
Kisqali + Femara Co-Pack 400 mg, 70 tabs per bottle |
01/03/2020 |
552.33 |
10594.71 |
11/09/2031 |
Single Source Drug |
1176 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078092361 |
Kisqali + Femara Co-Pack 600 mg, 91 tabs per bottle |
01/03/2020 |
690.41 |
13243.38 |
11/09/2031 |
Single Source Drug |
4331 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078086001 |
Kisqali 200 mg, 21 Tabs per bottle |
01/03/2020 |
276.16 |
5297.34 |
11/09/2031 |
Single Source Drug |
4420 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078086742 |
Kisqali 400 mg, 42 Tabs per bottle |
01/03/2020 |
552.33 |
10594.71 |
11/09/2031 |
Single Source Drug |
4568 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078087463 |
Kisqali 600 mg, 63 Tabs per bottle |
01/03/2020 |
690.41 |
13243.38 |
11/09/2031 |
Single Source Drug |
14532 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078066615 |
Mekinist 0.5 mg 30 tabs per bottle |
01/03/2020 |
182.95 |
3509.28 |
01/28/2032 |
Single Source Drug |
20572 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00065427325 |
PAZEO 0.007 Drops, 2.5mL |
01/03/2020 |
10.71 |
205.42 |
05/19/2032 |
Single Source Drug |
1237067 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078068415 |
Promacta 12.5 mg, 30 tabs per bottle |
01/03/2020 |
344.85 |
5271.32 |
02/01/2028 |
Single Source Drug |
8885 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078068515 |
Promacta 25 mg, 30 tabs per bottle |
01/03/2020 |
344.85 |
5271.32 |
02/01/2028 |
Single Source Drug |
35420 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078068615 |
Promacta 50 mg, 30 tabs per bottle |
01/03/2020 |
624.07 |
9539.41 |
02/01/2028 |
Single Source Drug |
46343 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078068715 |
Promacta 75 mg, 30 tabs per bottle |
01/03/2020 |
936.11 |
14309.12 |
02/01/2028 |
Single Source Drug |
23048 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078069899 |
Rydapt 25 mg - 56 tabs per bottle |
01/03/2020 |
467.55 |
8968.38 |
12/02/2030 |
Single Source Drug |
7953 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078069819 |
Rydapt 25 mg, 112 tabs per bottle |
01/03/2020 |
935.09 |
17936.75 |
12/02/2030 |
Single Source Drug |
2769 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00065414727 |
SIMBRINZA 1% / 0.2%, Drops, 8mL per bottle |
01/03/2020 |
8.95 |
171.68 |
10/30/2030 |
Single Source Drug |
872007 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078068266 |
Tafinlar 50 mg, 120 tabs per bottle |
01/03/2020 |
445.01 |
8536.05 |
10/15/2030 |
Single Source Drug |
4352 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078059287 |
Tasigna 150mg, 28 capsule per bottle, 4 bottles |
01/03/2020 |
962.73 |
14716.02 |
10/15/2030 |
Single Source Drug |
21978 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078052687 |
Tasigna 200mg, 28 capsule per bottle, 4 bottles |
01/03/2020 |
962.73 |
14716.02 |
10/15/2030 |
Single Source Drug |
21978 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00065026025 |
TRAVATAN Z 0.00004, Drops, 2.5mL per bottle |
01/03/2020 |
10.11 |
193.98 |
10/13/2029 |
Innovator Multiple Source Drug |
2226281 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00065026005 |
TRAVATAN Z 0.00004, Drops, 5mL per bottle |
01/03/2020 |
20.22 |
387.94 |
10/13/2029 |
Innovator Multiple Source Drug |
456823 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078067119 |
Tykerb 250 mg, 150 tabs per bottle |
01/03/2020 |
435.48 |
8353.31 |
09/18/2029 |
Single Source Drug |
12617 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000073 |
Novartis |
03/31/2020 |
00078067066 |
Votrient 200 mg 120 tabs per bottle |
01/03/2020 |
719.32 |
13797.84 |
10/19/2023 |
Single Source Drug |
33010 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968051408 |
Estradiol & Norethindrone Acetate 0.05-0.14 MG/DAY Patch Twice Weekly 8 EA UU |
01/01/2020 |
15.80 |
207.41 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/13/2014 |
Novartis |
None |
1 |
Not a matter of public record |
80.50 |
70.06 |
1998 |
23.75 |
None |
None |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968052508 |
Estradiol & Norethindrone Acetate 0.05-0.25 MG/DAY Patch Twice Weekly 8 EA UU |
01/01/2020 |
15.80 |
207.41 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/13/2014 |
Novartis |
None |
1 |
Not a matter of public record. |
80.40 |
69.97 |
1998 |
23.75 |
None |
None |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968662508 |
Estradiol 0.025 MG/24HR Patch Twice Weekly 8 EA UU |
01/01/2020 |
14.96 |
196.34 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968663708 |
Estradiol 0.0375 MG/24HR Patch Twice Weekly 8 EA UU |
01/01/2020 |
14.96 |
196.34 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968665008 |
Estradiol 0.05 MG/24HR Patch Twice Weekly 8 EA UU |
01/01/2020 |
14.96 |
196.34 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968667508 |
Estradiol 0.075 MG/24HR Patch Twice Weekly 8 EA UU |
01/01/2020 |
14.96 |
196.34 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968661008 |
Estradiol 0.1 MG/24HR Patch Twice Weekly 8 EA UU |
01/01/2020 |
14.96 |
196.34 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968555203 |
Methylphenidate 10 MG/9HR Patch 30 EA UU |
01/01/2020 |
30.20 |
396.32 |
10/07/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968555303 |
Methylphenidate 15 MG/9HR Patch 30 EA UU |
01/01/2020 |
30.20 |
396.32 |
10/07/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968555403 |
Methylphenidate 20 MG/9HR Patch 30 EA UU |
01/01/2020 |
30.20 |
396.32 |
10/07/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968555503 |
Methylphenidate 30 MG/9HR Patch 30 EA UU |
01/01/2020 |
30.20 |
396.32 |
10/07/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
Rx0000033 |
Novo |
03/31/2020 |
00169413212 |
Ozempic (0.25 or 0.5 MG/DOSE) Subcutaneous Solution Pen-injector 2 MG/1.5ML |
01/10/2020 |
38.62 |
811.05 |
06/21/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NNI holds a number of patents related to Ozempic and has included the expiration date for Patent #10335462 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Ozempic and did not acquire the product from a different company. |
Rx0000033 |
Novo |
03/31/2020 |
00169413602 |
Ozempic (1 MG/DOSE) Subcutaneous Solution Pen-injector 2 MG/1.5ML |
01/10/2020 |
38.62 |
811.05 |
06/21/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NNI holds a number of patents related to Ozempic and has included the expiration date for Patent #10335462 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Ozempic and did not acquire the product from a different company. |
Rx0000033 |
Novo |
03/31/2020 |
00169406012 |
Victoza 6mg/mL 2x3mL Prefilled Pens |
01/10/2020 |
30.72 |
645.24 |
07/09/2037 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NNI holds a number of patents related to Victoza. We've included the expiration date for Patent #9968659 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Victoza and did not acquire the product from a different company. |
Rx0000033 |
Novo |
03/31/2020 |
00169406013 |
Victoza 6mg/mL 3x3mL Prefilled Pens |
01/10/2020 |
46.08 |
967.86 |
07/09/2037 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NNI holds a number of patents related to Victoza. We've included the expiration date for Patent #9968659 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Victoza and did not acquire the product from a different company. |